Northwest Biotherapeutics (OTCMKTS:NWBO) Announces Quarterly Earnings Results

Northwest Biotherapeutics (OTCMKTS:NWBO) released its earnings results on Monday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $0.23 million for the quarter.

Northwest Biotherapeutics Stock Performance

Northwest Biotherapeutics stock traded down $0.02 during trading hours on Wednesday, hitting $0.21. The company had a trading volume of 3,911,649 shares, compared to its average volume of 3,229,775. The firm has a market cap of $293.89 million, a P/E ratio of -2.65 and a beta of -0.52. The company has a 50-day moving average price of $0.26 and a two-hundred day moving average price of $0.28. Northwest Biotherapeutics has a 1 year low of $0.20 and a 1 year high of $0.57.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.